What question did this study set out to answer?

To investigate the association of rare Alzheimer's disease variants, APP A673T and ABCA7 rs200538373-C, with circulating plasma β-amyloid levels and metabolic and cardiovascular parameters.

May 27, 2017Annals of Neurology

Decreased plasma β‐amyloid in the Alzheimer's disease APPA673T variant carriers

View Full Paper

Ask AI

Bookmark

Authors

HMHenna MartiskainenUniversity of Eastern Finland SHSanna‐Kaisa HerukkaUniversity of Eastern Finland ASAlena StančákováUniversity of Eastern Finland

Discussion

Member takes

Implication

Cohort study reveals lower plasma amyloid-beta levels in men carrying the protective APP A673T variant, indicating lifelong reductions in amyloid may protect against Alzheimer's disease.

Key Points

To investigate the association of rare Alzheimer's disease variants, APP A673T and ABCA7 rs200538373-C, with circulating plasma β-amyloid levels and metabolic and cardiovascular parameters.
Population-based cohort study examining healthy middle-aged and elderly men.
Quantified plasma concentrations of Aβ40 and Aβ42 alongside metabolic and cardiovascular health parameters across APP A673T carriers, ABCA7 rs200538373-C carriers, and controls.
Carriers of the protective APP A673T variant exhibited an average of 28% lower plasma levels of Aβ40 and Aβ42 compared with non-carrier controls and ABCA7 rs200538373-C carriers.
The observed reduction in circulating plasma Aβ provides clinical evidence that maintaining lower amyloid levels throughout life confers protection against Alzheimer's disease.

Cite This Study

Martiskainen et al. (2017) studied this question.

synapsesocial.com/papers/6a0e88eb4a1f6bc478043402 https://doi.org/10.1002/ana.24969

View Full Paper

Ask AI

Bookmark

Implication

Cohort study reveals lower plasma amyloid-beta levels in men carrying the protective APP A673T variant, indicating lifelong reductions in amyloid may protect against Alzheimer's disease.

Decreased plasma β‐amyloid in the Alzheimer's disease APPA673T variant carriers

Discussion

Member takes

Implication

Key Points

Cite This Study

Decreased plasma β‐amyloid in the Alzheimer's disease APPA673T variant carriers

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider